公开(公告)号：US20150273036A1

公开(公告)日：2015-10-01

申请号：US14435258

申请日：2013-10-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Lorenzo Tarli ,  Mario Contorni ,  Alessandro Bartalesi

IPC: A61K39/00 ,  C12N7/00 ,  A61K39/29 ,  A61K39/02 ,  A61K39/13

CPC classification number: A61K39/0018 ,  A61K39/0016 ,  A61K39/099 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2770/30034 ,  Y02A50/466

Abstract: The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.

Abstract translation: 本发明涉及包含不与交联剂如甲醛或戊二醛交联的无细胞百日咳抗原及其作为组合疫苗中的无细胞百日咳组分的用途的稳定组合物。 还公开了制备这些抗原和组合物的方法。

公开(公告)号：US09855324B2

公开(公告)日：2018-01-02

申请号：US14424362

申请日：2013-10-03

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Mario Contorni ,  Guido Grandi ,  Domenico Maione ,  Immaculada Margarit Y Ros

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/05 ,  A61K39/08 ,  A61K39/02 ,  A61K39/13 ,  A61K39/12 ,  C12N7/00 ,  A61K9/00 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K9/0019 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/12 ,  A61K39/13 ,  A61K47/646 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/32334 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group B streptococcus capsular saccharide conjugated to a carrier protein. The invention also provides a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

公开(公告)号：US12128094B2

公开(公告)日：2024-10-29

申请号：US17287268

申请日：2019-11-04

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Mario Contorni ,  Mariagrazia Pizza ,  Anja Seubert

IPC: A61P31/04 ,  A61K39/00

CPC classification number: A61K39/0018 ,  A61P31/04 ,  A61K2039/55505

Abstract: The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

公开(公告)号：US10568953B2

公开(公告)日：2020-02-25

申请号：US16269370

申请日：2019-02-06

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Mario Contorni ,  Lorenzo Tarli

IPC: A61K39/395 ,  A61K39/095 ,  A61K47/02 ,  A61K39/00

Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

公开(公告)号：US10245311B2

公开(公告)日：2019-04-02

申请号：US15604054

申请日：2017-05-24

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Mario Contorni ,  Lorenzo Tarli

IPC: A61K39/395 ,  A61K39/095 ,  A61K47/02 ,  A61K39/00

Abstract: Factor H binding protein (fHBP) has been proposed for use in immunizing against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminum hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminum hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminum hydroxyphosphate adjuvant.